Why is Moderna stock down 22.2% today?

Traders Union
All News
Stocks
Moderna slides 22.28% today

Highlights

Moderna and Merck reported that their mRNA-4157 melanoma vaccine with Keytruda cut recurrence or death risk by 49% versus Keytruda alone in Phase 3.
The FDA approved Moderna's mFLUSIVA flu vaccine for adults aged 50 and over, adding to its U.S. therapy offerings.
Shares of Moderna fell 22.28% to $135.52 despite overbought technical signals, with the five-day projected range spanning $95.08 to $162.62.

Positive vaccine milestones offset by persistent selling and R&D outlays

Moderna, in collaboration with Merck, announced positive Phase 3 results for its experimental mRNA-4157 melanoma vaccine combined with Keytruda, demonstrating a 49% reduction in risk of recurrence or death compared to Keytruda alone. The company also received FDA approval for its mFLUSIVA flu vaccine for adults aged 50 and older, expanding its U.S. therapy portfolio. Both developments were reported alongside continued management of net losses and increased investment in R&D, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees a sharp disconnect between Moderna’s headline breakthroughs and the violent 22% selloff. He warns that overbought technical readings highlight fragile sentiment, with RSI and Stochastic peaks suggesting vulnerable support at $128.88. Despite positive news on vaccines and product approvals, Kharitonov notes heavy profit-taking and persistent net losses undermine confidence in sustainability. The extreme volatility and gap down show market distrust of recent gains. "I remain cautious as technical euphoria clashes with heavy selling — traders should watch for a false recovery and defend against further downside risk."

Viktoras Karapetjanc, expert at Traders Union, believes Moderna’s pipeline momentum remains robust despite the dramatic pullback. He points to the successful Phase 3 melanoma vaccine results and the expanded therapy portfolio as powerful drivers for further growth. Karapetjanc stresses that the bullish trend structure above key moving averages offers multiple entry opportunities, even in volatile sessions. He expects institutional confidence to strengthen as positive clinical results translate into revenue potential. "The bullish structure remains intact — I see scope for renewed buying and upside toward $162.62 once sentiment stabilizes."

Jainam Mehta, market strategist, sees a rare divergence between momentum and price action after Moderna’s sharp gap down. He notes the overbought technicals may set up for a tactical bounce, but persistent selling pressure keeps risks elevated. Mehta views the $128.88 level as a pivot — a breakdown opens the door to a deeper retracement while a reversal could trigger a fast-moving recovery. "Watch for a contrarian entry opportunity if volatility fades and price holds above support."

Extreme overbought signals clash with sudden downside volatility

Moderna is trading well above its 20-day ($64.2), 50-day ($63.91), and 200-day ($47.6) moving averages, affirming a strong short-, medium-, and long-term bullish trend structure. Immediate support and resistance are marked by the near-term floor at $128.88 and the near-term ceiling at $150.7, with long-term trend confirmation supported by a bullish alignment between the 50-day and 200-day averages. Momentum is highly elevated, with the MACD signaling continued upward bias and the ADX indicating a neutral trend strength. Several overbought warnings are present: the RSI is at 92.21, Stochastic RSI reads 100, and the CCI has surged to 656.44. Bull/Bear Power stands at 99.16, confirming buyer dominance and an overbought condition. The Awesome Oscillator maintains a strong positive reading, supporting bullish momentum. Despite this technical backdrop, the stock is sharply lower today at $135.52, sliding $38.86 or 22.28% after a downside gap of $24.38 (13.98%), currently trading near session lows. Intraday volatility stands at 16.93%, and pressure remains after the opening gap down, indicating aggressive profit-taking or reaction to adverse news. Price action is at odds with bullish momentum, highlighting a sharp divergence between overbought technicals and heavy selling.

Earlier, analysts noted that Moderna’s breakthrough in personalized mRNA cancer vaccines, alongside its expanding pipeline, set high expectations for broad future growth. The current sharp selloff against a backdrop of bullish technical structure highlights increased volatility and calls for close attention to the $128.88 support and $150.7 resistance as near-term pivots for directional follow-through.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.